



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2008-002848-41/ Novartis Protocol ID CAPL180A2207

*A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia*

Trial CAPL180A2207 was cancelled with no patient enrollment and as such, no results will be reported.